DDInter822 DDInter1658
Glasdegib, also known as PF-04449913, is a small-molecule hedgehog signaling inhibitor selected under the group of benzimidazoles. In early research, benzimidazoles attracted large interest as they represented a class of inhibitors with low molecular weight, potent inhibitory activity, and lacking unstable functionality. The great lipophilicity of this group of compounds brought interest to further modification. This analysis concluded that the presence of p-cyano ureas presented good physicochemical and pharmacokinetic properties from which glasdegib was developed. Glasdegib was developed by Pfizer Inc and approved on November 21, 2018 by the FDA for the treatment of Acute Myeloid Leukemia (AML). Glasdegib targets cancerous cells by inhibiting the sonic hedgehog receptor smoothened (SMO), a transmembrane protein involved in the Hedgehog (Hh) signaling cascade. Aberrant of Hh signaling is one
Selpercatinib is a kinase inhibitor with enhanced specificity for RET tyrosine kinase receptors (RTKs) over other RTK classes.[A202055, A202052, L13604] Enhanced RET (Rearranged during transfection) oncogene expression is a hallmark of many cancers. Although multikinase inhibitors, including [cabozantinib], [ponatinib], [sorafenib], [sunitinib], and [vandetanib], have shown efficacy in RET-driven cancers, their lack of specificity is generally associated with substantial toxicity. Selpercatinib (LOXO-292) and pralsetinib (BLU-667) represent the first generation of specific RET RTK inhibitors for the treatment of RET-driven cancers.[A202049, A202055, A202052, L13604] Although selpercatinib is currently still under investigation in clinical trial NCT04211337, it was granted accelerated FDA approval on May 8, 2020, for specific RET-driven cancer indications. It is currently marketed under the brand name RETEVMO™ by Loxo Oncology Inc. Selpercatinib is also approved by the European Commission.
Glasdegib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Naloxegol
Glasdegib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Darolutamide
Glasdegib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Abametapir
Glasdegib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Levosalbutamol
Glasdegib {u} may lead to a major life threatening interaction when taken with {v} Bedaquiline
Glasdegib {u} may lead to a major life threatening interaction when taken with {v} Ivosidenib
Glasdegib may cause a minor interaction that can limit clinical effects when taken with Naloxegol
Glasdegib may cause a minor interaction that can limit clinical effects when taken with Darolutamide
Glasdegib may cause a moderate interaction that could exacerbate diseases when taken with Abametapir
Glasdegib may cause a moderate interaction that could exacerbate diseases when taken with Levosalbutamol
Glasdegib may lead to a major life threatening interaction when taken with Bedaquiline
Glasdegib may lead to a major life threatening interaction when taken with Ivosidenib